Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement

被引:48
作者
Applebaum, Mark A. [1 ]
Goldsby, Robert [1 ]
Neuhaus, John [2 ]
DuBois, Steven G. [1 ]
机构
[1] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, Dept Biostat, San Francisco, CA USA
关键词
Ewings; PNET; Ewing tumors; lymph node; outcomes research; SEER; PROGNOSTIC-FACTORS; CHEMOTHERAPY; BONE; INTERGROUP; TUMORS; ONCOLOGY; FAMILY; TRIAL; 2ND;
D O I
10.1002/pbc.24053
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background A minority of patients with Ewing sarcoma present with regional lymph node involvement. We investigated if patient characteristics and outcomes differ between patients with Ewing sarcoma with and without regional node involvement. Procedure Patients <40 years of age with Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) reported to the SEER database from 1973 to 2008 were evaluated based on the presence (n?=?91) or absence (n?=?1,361) of regional node involvement. Patient characteristics were analyzed using Fisher exact tests. Overall survival was estimated by KaplanMeier methods and evaluated using log-rank tests and Cox models. Results Patients with regional node involvement were more likely to have extraskeletal primary tumors (65.9% vs. 31.2%; P?<?0.001) and axial tumors (71.1% vs. 59.6%; P?=?0.03) compared to patients without regional node involvement. The incidence of regional node involvement was 12.4% for patients with extraskeletal primary tumors compared to 3.2% for patients with skeletal tumors. Five-year overall survival from diagnosis was inferior for patients with regional node involvement compared to those without regional node involvement (45.9% vs. 60.3%; P?<?0.001). On multivariate analysis, regional node involvement was predictive of inferior overall survival independent of age, metastatic status, tumor site, and soft tissue origin (hazard ratio 1.59; 95% CI 1.162.19). Conclusions Patients with extraskeletal Ewing sarcoma should undergo evaluation for regional node involvement. If validated, our findings indicate that regional node involvement may be an independent adverse prognostic factor in Ewing sarcoma, and potentially useful in risk-stratifying patients with otherwise localized disease. Pediatr Blood Cancer 2012;59:617620. (c) 2011 Wiley Periodicals, Inc.
引用
收藏
页码:617 / 620
页数:4
相关论文
共 18 条
[1]   Clinical Features and Outcomes in Patients with Extraskeletal Ewing Sarcoma [J].
Applebaum, Mark A. ;
Worch, Jennifer ;
Matthay, Katherine K. ;
Goldsby, Robert ;
Neuhaus, John ;
West, Daniel C. ;
DuBois, Steven G. .
CANCER, 2011, 117 (13) :3027-3032
[2]   Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli [J].
Bacci, G ;
Ferrari, S ;
Bertoni, F ;
Rimondini, S ;
Longhi, A ;
Bacchini, P ;
Forni, C ;
Manfrini, M ;
Donati, D ;
Picci, P .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :4-11
[3]   Prognostic factors in Ewing's tumor of bone:: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study group [J].
Cotterill, SJ ;
Ahrens, S ;
Paulussen, M ;
Jürgens, HF ;
Voûte, PA ;
Gadner, H ;
Craft, AW .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3108-3114
[4]   Ifosfamide-containing chemotherapy in Ewing's sarcoma: The second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's tumor study [J].
Craft, A ;
Cotterill, S ;
Malcolm, A ;
Spooner, D ;
Grimer, R ;
Souhami, R ;
Imeson, J ;
Lewis, I .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3628-3633
[5]   Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84 [J].
Flamant, F ;
Rodary, C ;
Rey, A ;
Praquin, MT ;
Sommelet, D ;
Quintana, E ;
Theobald, S ;
Brunat-Mentigny, M ;
Otten, J ;
Voute, PA ;
Habrand, JL ;
Martelli, H ;
Barrett, A ;
Terrier-Lacombe, MJ ;
Oberlin, O .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (07) :1050-1062
[6]   Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study [J].
Granowetter, Linda ;
Womer, Richard ;
Devidas, Meenakshi ;
Krailo, Mark ;
Wang, Chenguang ;
Bernstein, Mark ;
Marina, Neyssa ;
Leavey, Patrick ;
Gebhardt, Mark ;
Healey, John ;
Shamberger, Robert Cooper ;
Goorin, Allen ;
Miser, James ;
Meyer, James ;
Arndt, Carola A. S. ;
Sailer, Scott ;
Marcus, Karen ;
Perlman, Elizabeth ;
Dickman, Paul ;
Grier, Holcombe E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) :2536-2541
[7]   Factors associated with tumor volume and primary metastases in Ewing tumors:: Results from the (EI)CESS studies [J].
Hense, HW ;
Ahrens, S ;
Paulussen, M ;
Lehnert, M ;
Jürgens, H .
ANNALS OF ONCOLOGY, 1999, 10 (09) :1073-1077
[8]  
JURGENS H, 1988, CANCER, V61, P23, DOI 10.1002/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO
[9]  
2-M
[10]   Diagnostic value of PET/CT for the staging and restaging of pediatric tumors [J].
Kleis, Margit ;
Daldrup-Link, Heike ;
Matthay, Katherine ;
Goldsby, Robert ;
Lu, Ying ;
Schuster, Tibor ;
Schreck, Carole ;
Chu, Philip W. ;
Hawkins, Randall A. ;
Franc, Benjamin L. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (01) :23-36